Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

Whether primary prophylactic pegylated‐granulocyte‐colony stimulating factor (PEG‐G‐CSF) should be administered immediately after the initiation of ramucirumab plus docetaxel (DR) to prevent the occurrence of febrile neutropenia (FN) is unclear. Our retrospective study aimed to elucidate whether PEG...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Atsuto Mouri, Kyoichi Kaira, Ayako Shiono, Ou Yamaguchi, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2019-04-01
Colecção:	Thoracic Cancer
Assuntos:	Docetaxel prophylactic G‐CSF ramucirumab
Acesso em linha:	https://doi.org/10.1111/1759-7714.13022
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!